Treatment of these cells with cisplatin or hydrogen peroxide induces complete mitochondrial DNA damage in OV 2008 cells, while only partial DNA-destruction is observed in C13 cells, strongly suggesting that mitochondria are resistant to cisplatin and oxidative stress response. Continuous oxygen consumption of these cells monitored by a multi-channel dissolved oxygen meter is 1.70-fold higher in OV 2008 cells than C13 cells and the oxygen consumption was decreased by 30% in C13 cells, suggesting mitochondrial respiratory malfunction in these cells. The hypothesis generated here is that mitochondrial DNA resistance to cisplatin and oxidative stress response might be one of the main characteristics concerning the lower level of apoptosis induced by cisplatin. However, the mechanism by which the mitochondrial DNA encoded molecule is involved in cisplatin resistance remains to be determined.
Introduction
Platinum drugs remain one of the most important chemotherapeutic agents for ovarian cancer treatment. The resistance to cisplatin is a major obstacle for successful cancer therapy. Although significant biochemical changes in the cisplatinresistant cells including increased drug efflux, decreased drug influx, increased cellular glutathione level, and DNA repair function have been described, the mechanisms resulting in cellular cisplatin resistance remains unclear. A wide range of chemotherapeutic drugs including cisplatin induce death in malignant cells by triggering apoptosis (1) . Cisplatin specifically has been shown to induce apoptosis by i) induction of the Fas ligand on the surface of tumor cells, resulting in killing of the Fas-sensitive subpopulation, ii) the direct activation of caspase-8, and iii) the integration of various cell stress signals via the 'activation' of mitochondria. One crucial event in the apoptotic pathway is the cytochrome c release from the mitochondria into the cytosol. Cytochrome c initiates the assembly of the apoptotic protease-activating factor 1 and procaspase-9 into a holoenzyme complex which in turn activates the initiator caspase-9. This activates downstream caspase-3, resulting in DNA fragmentation and apoptosis. A current view of drug-induced apoptosis emphasizes the role of different cell organelles as stress sensors that reroute the signal via mitochondria or other pathways (2, 3) . Alterations in mitochondria (4, 5) or its associated apoptotic pathway play an important role in acquiring drug resistance. There are two distinct hypotheses concerning the correlation between drug sensitivity and mitochondria. Liang and Ullyatt (6) reported an increased cisplatin sensitivity in mitochondrial DNA depleted U937 cells. They demonstrated that these cells continued to respond to cisplatin by an apoptotic death. Thus mitochondrial DNA-encoded molecules may play a role in the sensitivity of cells to undergo a cisplatin-induced apoptotic death, but may not be required for cells to undergo apoptosis.
On the other hand, Park et al (7) have shown that mitochondrial DNA-depleted SK-Hep1 hepatoma cells with frequent mitochondrial DNA mutations are resistant to various forms of cell death, such as oxidative stress and chemotherapeutic agents.
In the present study, we have focused on the characteristics of mitochondria in cisplatin resistant cells, particularly the direct interaction between cisplatin and mitochondrial DNA. We will show that platinum-resistant cells are characterized by mitochondrial respiratory abnormalities and contain mitochondrial DNA with resistance to cisplatin and to reactive oxygen. The hypothesis generated here is that the mitochondrial DNA encoded molecules might participate in the resistance to cisplatin-induced apoptosis.
Materials and methods
Reagents. Cisplatin was obtained from Bristol-Myers Squibb K.K. Hoechst-33342 was purchased from Sigma Chemical Co. DiOC 6 was purchased from Molecular Probes, Inc. The caspase-3 inhibitor Ac-DEVD-CHO and caspase-9 inhibitor were purchased from Calbiochem, La Jolla, CA.
Tumor cell lines. The human cell line OV 2008 was established from a patient with a serous cystadenocarcinoma of the ovary (8) . A resistant subline, designated OV 2008/C13 * 5.25 (C13), was obtained by 13 monthly selections to cisplatin exposure. The cells were cultured at 37˚C in 95% air and 5% CO 2 . They were grown in RPMI-1640 medium supplemented with 5% heat inactivated fetal bovine serum, 2 mM glutamine, 100 Units/ml penicillin, and 100 μg/ml streptomycin.
Colony assays. Colony forming assays were used to assess the effect of the caspase-3 inhibitor Ac-DEVD-CHO and caspase-9 inhibitor on drug sensitivity. Cell suspensions, containing 600 cells, were plated on tissue culture dishes. Drug solution was added to triplicate plates at each drug concentration. After 30 min preincubation in the presence of caspase inhibitor, cells were treated with cisplatin and either one of the above inhibitors concurrently for 72 h. Control cells were incubated with either cisplatin or the inhibitor or vehicle alone. Following drug exposure the drug-containing medium was aspirated and replaced with a drug free medium. Colonies of over 60 cells were counted macroscopically.
Detection of apoptosis. Nuclear staining by Hoechst-33342 was viewed and photographed using Zeiss fluorescence microscope. Cells with typical apoptotic nuclear morphology such as nuclear shrinkage, fragmentation, and condensation were identified and counted using randomly selected fields on numbered slides with the counter unaware of the treatment, so as to avoid experimental bias. The percentage of induction of apoptosis was estimated by counting these cells in duplicate samples of 400 cells. 8 cells were harvested in DMEM. Cells were pelleted and washed once with homogenization buffer (250 mM sucrose, 1 mM Tris-HCl, and 1 mM EDTA, and 1 mg/ml BSA, pH 7.4). The final pellet of cells was resuspended in homogenization buffer to a volume of 7 ml and homogenized in a tissue grinder with a tight pestle until at least 95% of the cells were disrupted. The homogenate was centrifuged at 800 x g for 10 min at 4˚C. The supernatant was removed and saved, and the pellet was resuspended and centrifuged again at 800 x g for 10 min. The supernatants were then pooled and centrifuged at 9,400 x g for 10 min at 4˚C. The pellet was resuspended in homogenization buffer and centrifuged again at 9,400 x g, and the final pellet was suspended in homogenization buffer to a final volume of about 5 mg protein/ml.
Assessment of mitochondrial membrane potential (ΔΨm
Detection of mitochondrial DNA damage. DNA was extracted according to the instructions of the manufacturer. To detect mitochondrial DNA damage, the entire coding region of the mitochondrial genome was amplified by long range PCR with the use of primers 59-CCCACAGTTTATGTAGC TTACCTCCTCA-39 (nucleotides 571-598 of the Cambridge human mitochondrial DNA sequence) and 59-TTGATTGCT GTACTTGCTTGTAAGCATG-39 (nucleotides 16, 193 ). Long range PCR was performed with the Expand Long Template PCR system (Boehringer Mannheim) according to the manufacturer's instructions with the following modifications: Denaturing temperature 92˚C, annealing temperature 65˚C, extension time 14 min during the first 10 cycles and 14 min plus 20 sec for each consecutive cycle during the subsequent 12 cycles. The final extension time was 14 min. The 15.6-kb PCR products were resolved on a 0.7% agarose gel and visualized by ethidium bromide. As a positive control, mitochondrial DNA damage was induced in the OV 2008 or C13 cells by treatment with H 2 O 2 in concentrations ranging from 6.25 to 50 μM at 37˚C for 1 h. To detect cisplatin-induced DNA damage, OV 2008 and C13 cells, respectively, were treated with cisplatin.
Measurement of oxygen consumption. Cellular oxygen consumption was determined by disposable oxygen electrode sensor and multi-channel dissolved oxygen meter (Daikin Co. DOX-96). The continuous oxygen consumption (slop of dissolved oxygen, SDO) and the accumulated total amount of oxygen consumption for 8 h (difference in the area under the curve, AUC) were calculated in OV 2008 and C13 cells.
Statistical analysis. Differences between samples or the groups of samples were determined by Student's t-test using two-sided p-values.
Results
Apoptotic fraction. The percentage of induction of apoptosis was estimated by counting the frequency of Hoechst-33342 stained cells that contained apoptotic bodies. Fig. 1 shows that, when the cells were evaluated 24 h after the end of drug exposure, cisplatin induced 3.90±1.01 (SD; n=3) (p<0. Inhibitory effect of Ac-DEVD-CHO and caspase-9 inhibitor on cisplatin cytotoxicity. To assess how the caspase pathways involved in the effect of cisplatin, the cells were exposed to cisplatin in the presence or absence of Ac-DEVD-CHO or the caspase-9 inhibitor. The bars in Fig. 2 demonstrate that cisplatin at an IC 50 concentration alone produced a 48% reduction on clonogenic survival in OV 2008 cells and in C13 cells. Under these culture conditions, Ac-DEVD-CHO blocked cisplatin cytotoxicity and recovered clonogenic survival by 22% both in OV 2008 and C13 cells. Further, the caspase-9 inhibitor recovered survival by 30% in OV 2008 and 31% in C13 cells. Although these inhibitors slightly decreased their survival, the data suggest that all the caspase cascades are well functioning in resistant cells and that the decreased rate of apoptosis induction might be due to a possible mitochondrial functional change.
Mitochondrial membrane potential (ΔΨm).
To define alterations in mitochondrial function in cisplatin-resistant C13 cells, we assessed the mitochondrial transmembrane potential using potential-sensitive fluorochrome DiOC 6 . Fig. 3 demonstrates that the polarized cell population in C13 was 96.5% determined by the area under the curve in Fig. 3I , while all of the cisplatin-sensitive OV 2008 cells are depolarized (Fig. 3II) . This is consistent with the evidence of elevated mitochondrial transmembrane potential in resistant cells.
Detection of mitochondrial DNA damage. Because cisplatin has been reported to cause single strand breaks on incorporation into nuclear DNA after conversion to active metabolites, we investigated whether cisplatin would have a direct damaging effect on mitochondrial DNA. Fig. 4 shows that with a PCR-based method, complete damage to mitochondrial DNA was noted during the treatment of OV 2008 cells with cisplatin (Fig. 4, lane 5) , whereas slight mitochondrial DNA was detectable in C13 cells after incubation with cisplatin (Fig. 4, lane 10) . Further, concentration-dependent damage to mitochondrial DNA was detected after incubation with H 2 O 2 known to induce DNA damage in both cells. After treatment with a maximum concentration of H 2 O 2 , mitochondrial DNA was observed in the C13 cells whereas complete damage was noted in OV 2008 cells (Fig. 4, lanes 1-4 and 6-9 ). This suggests that mitochondria in cisplatin-resistant cells are resistant to cisplatin as well as hydrogen peroxide.
Measurement of oxygen consumption.
To monitor the mitochondrial respiratory activity in cisplatin-resistant cells, we focused on the respiration volume as its signal. Respiration 
Discussion
Cisplatin is capable of initiating the mitochondrial death pathway directly and inducing tumor cell death (11, 12) . In the mitochondrial pathway, the instability of mitochondria leads to the redistribution of cytochrome c into the cytoplasm, which initiates the formation of the apoptosome and the sequential activation of caspase-9 and caspase-3. In this regard, there are three novel observations in this study: i) Despite the significantly decreased apoptotic level in the platinum-resistant cells, the downstream events following the release of cytochrome c from the mitochondria, such as caspase-9, -3, are functioning well in these cells. ii) The mitochondrial DNA in the platinum-resistant cells is highly resistant to cisplatin as well as oxidative stress. iii) Platinumresistant cells decreased oxygen consumption. These results suggest that one of the major cisplatin-resistant mechanisms lies in the protective function of mitochondria from DNAdamaging agents.
Classical studies have revealed that the drug-resistant phenotype can be significantly associated with resistance to apoptosis (13, 14) . Our above data strongly indicate that changes at the mitochondrial level are not the secondary characteristics in acquired resistant cells but could impact on the resistance of these cells to undergo drug-induced apoptosis. Alterations in the mitochondrial structure and function occur early during apoptosis before the nuclear or chromatin structure is affected (15) . Early findings include a reduction in mitochondrial membrane potential as shown in our data, affected by the opening of permeability transition pores. Regulation of these factors could enhance the platinum sensitivity and reverse the platinum resistance (16) .
Cytotoxicity of platinum drugs is based on the interaction with DNA by producing DNA adducts. In eukaryotic cells there are two distinct genomes; one is in the nucleus, and the other is in the mitochondria. These two are able to be targets of platinum attack. Our major interest is how these alterations in mitochondrial DNA characteristics are involved in cisplatin resistance. Park et al argued that the increased manganese superoxide dismutase expression in mitochondrial DNA-depleted SK-Hep1 cells could affect the intracellular metabolism of exogenous reactive oxygen species (7) . This indicats that acquired resistance to oxidative stress and doxorubicine in these cells might be the secondary outcome of metabolic change induced by mitochondrial DNA depletion. Whereas, concerning the platinum agents, accumulating evidence has suggested that mitochondrial DNA may be directly involved in the resistance to cisplatin-induced apoptosis. The most important mechanism of cisplatin cell cytotoxicity is platinum-DNA crosslink formation. The study conducted by Liang and Ullyatt (6) implies that mitochondrial DNA-encoded molecules may play a role in the sensitivity of cells to undergo a cisplatin-induced apoptotic death. Our data demonstrating mitochondrial DNA resistance to cisplatin in platinum-resistant cells provides the possibility that the alteration of mitochondrial DNA resulted in a decreased level of apoptotic induction.
Another point to be addressed is the mechanism of mitochondrial DNA resistance in cisplatin resistant cells. The damage and repair of nuclear DNA has been investigated intensely in cisplatin-resistant cells. Recently, DNA damage and repair has come of interest in that defects in the mitochondrial genomes are associated with a variety of chemotherapeutic agents that work through the mitochondrial DNA damage including platinum (17, 18) . A higher level and a decreased removal in mitochondrial DNA adducts by cisplatin as compared to nuclear DNA (19) or minimal repair of cisplatin intrastrand crosslinks in mitochondrial DNA (20) have been discussed, however, no correlation between cisplatin resistance and cisplatin-induced mitochondrial DNA damage has been reported. Although our data on platinum resistant cells contain a platinum-resistant mitochondrial DNA,we could not determine whether this was an increased level of removal in mitochondrial DNA adducts or an enhanced repair function of cisplatin intrastrand crosslinks in mitochondrial DNA.
The data presented in this article does not prove that there is an association among the elevated mitochondrial transmembrane potential (ΔΨm), the decreased oxygen consumption, and mitochondrial DNA resistance. No matter how these characteristics might be involved in cisplatin resistance independently or in association with each other, regulating the mitochondrial function could be sufficient to reverse the platinum resistance. Orobol, a phosphatidyl inositol-4 kinase inhibitor, could enhance cisplatin sensitivity in ovarian carcinoma cells by regulating the mitochondrial transmembrane potential ΔΨm (16) . One other method by which one can control the function of mitochondria is to activate the enzyme protein kinase C; this endogenous enzyme stimulates the mitochondrial function in the cell (21) .
It has been suggested that the activation of cellular protein kinase C could enhance the cell's sensitivity to cisplatin (22, 23) . Based upon our data, we propose that clinical trials be conducted to test whether the strategies used to control the function of mitochondria may overcome cisplatin resistance. 
